Premium
The combination of an inclusive novel agent treatment strategy, pre‐emptive therapy dose reduction, and prolonged therapy results in good outcomes in elderly myeloma patients
Author(s) -
Ediriwickrama Nadishani,
Oyebamiji Titi,
Munisamy Sreetharan,
Garland Paula,
Cuthill Kirsty,
Benjamin Reuben,
Ceesay M. Mansour,
Bowcock Stella
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15848
Subject(s) - medicine , multiple myeloma , bortezomib , cancer , incidence (geometry) , regimen , lenalidomide , pomalidomide , clinical trial , oncology , physics , optics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom